VBWG

17 related results for ACE


Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

Vascular Biology in Clinical Practice © Vol. 6, No. 3

A HOPE FOR PEACE? Update on the role of ACE inhibition in CAD patients

This monograph, A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

Vascular Biology in Clinical Practice © Vol. 4, No. 3

Peri-interventional care: Rationale for ACE manipulation

This monograph, Peri-interventional care: Rationale for ACE manipulation , is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women.

Preventing stroke with ACE inhibition

Each year, approximately 750,000 Americans suffer a first or recurrent stroke.

Curriculum Update # 7

Managing renal disease for risk reduction: The expanding role of ACE inhibition

Chronic renal disease is a problem of increasing magnitude in the United States.

Vascular Biology in Clinical Practice © Vol. 3, No. 2

New insights into the antiatherosclerotic potential of ACE inhibition

This monograph, New insights into the antiatherosclerotic potential of ACE inhibition is offered as part of a series of continuing medical education programs from the University of Florida College of Medicine.

SECURE: ACE inhibition retards the progression of atherosclerosis

Final results of the Study to Evaluate Carotid Ultrasound changes with Ramipril and vitamin E (SECURE) have been published and confirm that treatment with ramipril 10 mg slows the progression of atherosclerosis, while treatment with vitamin E has no apparent effect.

Angiotensin-(1-7): New insights into the benefits of tissue ACE inhibition

Emerging new data are expanding our understanding of the renin-angiotensin system (RAS).

Angiotension type 1 receptor blockade versus ACE inhibition in the treatment of heart failure: Results of 3 clinical trials

Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure.

Curriculum Update #3

Clinical Trials Update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

This Curriculum Update highlights important recent trials of tissue ACE inhibition in patients with cardiovascular disease and preserved left ventricular function.

Vascular Biology in Clinical Practice © Vol. 1, No. 4

Clinical trials update: Tissue ACE inhibition offers new hope for treating cardiovascular disease

Advances in vascular biology bring physicians the opportunity to apply new concepts in the treatment of patients with cardiovascular disease.

Data and Commentary: The BANFF Study

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease

J Am Coll Cardiol.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD.